SAB BIOTHERAPEUTICS INC

Explore how SAB Biotherapeutics, a Nasdaq‑listed biopharma, is pioneering immune‑based therapies to tackle complex diseases—and what this means for investors.

Investors weigh SAB Biotherapeutics’ steep stock decline as the company tackles clinical‑stage hurdles, revealing risks and potential breakthroughs in biotech innovation.